Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jason Coloma
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 141
- Beta
- 2.15
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 9.83
Financials
Revenue
$0.00-100.0%Net Income
$-44.73MEBITDA
$-43.80MFree Cash Flow
$-15.16MEPS (diluted)
$-0.76Shares Outstanding (diluted)
59.00M+34.8%Operating Expenses
$48.03MCash & Debt
$411.09MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-131.12M | $-3.05 |
| 2024 | $167.50M | $52.23M | $0.08 |
| 2023 | $0.00 | $-100.42M | $-2.29 |
| 2022 | $0.00 | $-114.94M | $-2.63 |
Valuation
MAZEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-41.67%Social Signal Score
Mentions (5)
- Newsfool.com·24d ago·Negative
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000 Chief Medical Officer Harold Bernstein sold 9,705 shares for ~$255,000 on September 4, 2026. The transaction involved shares equal to 100% of the insider's directly held common stock before the filing.
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
…e Therapeutics to Participate in Three Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate in three upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference; fireside chat on Wednesday, September 9, 2026…
View source ↗ - Newsseekingalpha.com·40d ago·Neutral
Maze Therapeutics: Intriguing Kidney Disease Assets Put This On The Watchlist Maze Therapeutics, Inc. has advanced two lead precision medicine programs, MZE782 for PKU and MZE829 for APOL1-mediated kidney disease, with significant clinical progress. MZE782 demonstrated a best-in-class pharmacodynamic profile in Phase 1, supporting a transformative potential for PKU management; Phase 2 is set for mid-2026. MZE829 achieved strong uACR reductions in early Phase 2 data for AMKD, but faces competitio
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
Maze Therapeutics Announces Appointments to Its Board of Directors Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., join Maze's Board of Directors, adding to the Company's deep bench of clinical and industry experience
View source ↗ - Newsglobenewswire.com·55d ago·Positive
Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027 Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongoing; topline data expected in 2027 Phase 2 trial of MZE782 in CKD on track for H1 2027 initiation Strong balance sheet with $495 million in cash, cash equivalents and marketable securities supports expected runway into 2029 SOUTH SAN
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.79 per share
Typical surprise -4.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.76 vs $-0.72miss
- Tue, May 12$-0.45 vs $-0.43miss
- Wed, Mar 25$-0.65 vs $-0.73beat
- Thu, Nov 6$-0.66 vs $-0.74beat
- Tue, Aug 12$-0.77 vs $-0.79beat
- Wed, May 14$-1.15 vs $-0.76miss
Estimates and results for MAZE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MAZE officers and directors.
- Bought
- —
- Sold
- $10.7m
0 trades
53 trades
- Coloma Jason Vsold
- Coloma Jason Vsold
- Bernstein Haroldsold
- Dandekar Atulsold
- Bernstein Haroldsold
- Courtney Phillipssold
- Courtney Phillipssold
- Dandekar Atulsold
47 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MAZE.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.